Metabolic disease-derived peripheral blood mononuclear cells (PBMCs) are isolated from donors diagnosed with metabolic disorders, such as type 2 diabetes, non-alcoholic steatohepatitis (NASH), and obesity-related conditions. These cells serve as a valuable tool for studying immune-metabolic interactions, inflammatory responses, and disease progression mechanisms. Available with donor-specific data, they support translational research in drug development, biomarker discovery, and personalized medicine approaches.